Limits...
Decreased expression of Beclin‑1 is significantly associated with a poor prognosis in oral tongue squamous cell carcinoma.

Hu Z, Zhong Z, Huang S, Wen H, Chen X, Chu H, Li Q, Sun C - Mol Med Rep (2016)

Bottom Line: Furthermore, MTT and colony formation assays were performed to investigate the effect of Beclin‑1 on the proliferation and clonogenicity of OTSCC cells.It was demonstrated that Beclin‑1 expression was significantly decreased in the majority of the 14 OTSCC tissues and the 5 OTSCC cell lines relative to the matched non‑cancerous tissues and the normal tongue epithelial cell line, respectively.The in vitro assays indicated that the overexpression of Beclin‑1 significantly inhibits the proliferation and clonogenicity of OTSCC cells.

View Article: PubMed Central - PubMed

Affiliation: Department of Head and Neck Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China.

ABSTRACT
The autophagy-related gene Beclin-1 is critical in the regulation of tumourigenesis and progression, but its role in oral tongue squamous cell carcinoma (OTSCC) has not yet been reported. This study aimed to investigate Beclin‑1 expression and its significance in OTSCC. Beclin‑1 expression was assessed by reverse transcription‑quantitative polymerase chain reaction or western blot analysis in 14 OTSCC tissues and matched adjacent noncancerous tissues as well as in 5 OTSCC cell lines and a normal tongue epithelial cell line. Beclin‑1 protein expression was examined by immunohistochemistry in 133 OTSCC specimens, and the correlation between Beclin‑1 expression and clinicopathological features was investigated. Furthermore, MTT and colony formation assays were performed to investigate the effect of Beclin‑1 on the proliferation and clonogenicity of OTSCC cells. It was demonstrated that Beclin‑1 expression was significantly decreased in the majority of the 14 OTSCC tissues and the 5 OTSCC cell lines relative to the matched non‑cancerous tissues and the normal tongue epithelial cell line, respectively. Immunohistochemistry analysis revealed that decreased Beclin‑1 expression was significantly correlated with poor differentiation, lymph node metastasis, advanced clinical tumour‑node‑metastasis stage, and a poor prognosis in patients with OTSCC. The in vitro assays indicated that the overexpression of Beclin‑1 significantly inhibits the proliferation and clonogenicity of OTSCC cells. These results demonstrate that Beclin‑1 acts as a tumour suppressor in the development or progression of OTSCC and that Beclin‑1 may represent a novel prognostic marker for patients with OTSCC.

No MeSH data available.


Related in: MedlinePlus

Protein expression of Beclin-1 by immunohistochemistry (magnification, ×200). (A) Beclin-1 expression in the normal tongue epithelium. (B) Intermediate expression of Beclin-1 in OTSCC tissue. (C) Low expression of Beclin-1 in OTSCC tissue. (D) High expression of Beclin-1 in OTSCC tissue. OTSCC, oral tongue squamous cell carcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940089&req=5

f2-mmr-14-02-1567: Protein expression of Beclin-1 by immunohistochemistry (magnification, ×200). (A) Beclin-1 expression in the normal tongue epithelium. (B) Intermediate expression of Beclin-1 in OTSCC tissue. (C) Low expression of Beclin-1 in OTSCC tissue. (D) High expression of Beclin-1 in OTSCC tissue. OTSCC, oral tongue squamous cell carcinoma.

Mentions: To further verify the expression of Beclin-1, an immunohistochemical assay was performed on 133 OTSCC specimens. As shown in Fig. 2, Beclin-1 protein was expressed in the cytoplasm. The decrease in Beclin-1 expression was closely correlated with poor differentiation, lymph node metastasis, and advanced clinical tumour-node-metastasis (TNM) stage of OTSCC (Table I). Notably, the five-year overall survival rate in the patients with no or low Beclin-1 expression was 47.5%, significantly shorter than that of the patients with high Beclin-1 expression (70.8%) (Fig. 3, P<0.01).


Decreased expression of Beclin‑1 is significantly associated with a poor prognosis in oral tongue squamous cell carcinoma.

Hu Z, Zhong Z, Huang S, Wen H, Chen X, Chu H, Li Q, Sun C - Mol Med Rep (2016)

Protein expression of Beclin-1 by immunohistochemistry (magnification, ×200). (A) Beclin-1 expression in the normal tongue epithelium. (B) Intermediate expression of Beclin-1 in OTSCC tissue. (C) Low expression of Beclin-1 in OTSCC tissue. (D) High expression of Beclin-1 in OTSCC tissue. OTSCC, oral tongue squamous cell carcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940089&req=5

f2-mmr-14-02-1567: Protein expression of Beclin-1 by immunohistochemistry (magnification, ×200). (A) Beclin-1 expression in the normal tongue epithelium. (B) Intermediate expression of Beclin-1 in OTSCC tissue. (C) Low expression of Beclin-1 in OTSCC tissue. (D) High expression of Beclin-1 in OTSCC tissue. OTSCC, oral tongue squamous cell carcinoma.
Mentions: To further verify the expression of Beclin-1, an immunohistochemical assay was performed on 133 OTSCC specimens. As shown in Fig. 2, Beclin-1 protein was expressed in the cytoplasm. The decrease in Beclin-1 expression was closely correlated with poor differentiation, lymph node metastasis, and advanced clinical tumour-node-metastasis (TNM) stage of OTSCC (Table I). Notably, the five-year overall survival rate in the patients with no or low Beclin-1 expression was 47.5%, significantly shorter than that of the patients with high Beclin-1 expression (70.8%) (Fig. 3, P<0.01).

Bottom Line: Furthermore, MTT and colony formation assays were performed to investigate the effect of Beclin‑1 on the proliferation and clonogenicity of OTSCC cells.It was demonstrated that Beclin‑1 expression was significantly decreased in the majority of the 14 OTSCC tissues and the 5 OTSCC cell lines relative to the matched non‑cancerous tissues and the normal tongue epithelial cell line, respectively.The in vitro assays indicated that the overexpression of Beclin‑1 significantly inhibits the proliferation and clonogenicity of OTSCC cells.

View Article: PubMed Central - PubMed

Affiliation: Department of Head and Neck Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China.

ABSTRACT
The autophagy-related gene Beclin-1 is critical in the regulation of tumourigenesis and progression, but its role in oral tongue squamous cell carcinoma (OTSCC) has not yet been reported. This study aimed to investigate Beclin‑1 expression and its significance in OTSCC. Beclin‑1 expression was assessed by reverse transcription‑quantitative polymerase chain reaction or western blot analysis in 14 OTSCC tissues and matched adjacent noncancerous tissues as well as in 5 OTSCC cell lines and a normal tongue epithelial cell line. Beclin‑1 protein expression was examined by immunohistochemistry in 133 OTSCC specimens, and the correlation between Beclin‑1 expression and clinicopathological features was investigated. Furthermore, MTT and colony formation assays were performed to investigate the effect of Beclin‑1 on the proliferation and clonogenicity of OTSCC cells. It was demonstrated that Beclin‑1 expression was significantly decreased in the majority of the 14 OTSCC tissues and the 5 OTSCC cell lines relative to the matched non‑cancerous tissues and the normal tongue epithelial cell line, respectively. Immunohistochemistry analysis revealed that decreased Beclin‑1 expression was significantly correlated with poor differentiation, lymph node metastasis, advanced clinical tumour‑node‑metastasis stage, and a poor prognosis in patients with OTSCC. The in vitro assays indicated that the overexpression of Beclin‑1 significantly inhibits the proliferation and clonogenicity of OTSCC cells. These results demonstrate that Beclin‑1 acts as a tumour suppressor in the development or progression of OTSCC and that Beclin‑1 may represent a novel prognostic marker for patients with OTSCC.

No MeSH data available.


Related in: MedlinePlus